Inspire Medical Systems (INSP)
NYSE:INSP
Want to see INSP full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.24Last Year’s EPS
0.45Same Quarter Last Year
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced/Neutral — The company delivered modest revenue growth, margin expansion, stronger operating cash flow, a solid cash position, and meaningful clinical progress, but faces material near-term headwinds from coding and reimbursement uncertainty and the WISER pilot that prompted a significant revenue guide reduction and short-term profitability pressure. Management outlined actions to mitigate the disruption (education, field reimbursement hiring, inventory strategy, targeted investments) and expects improvement later in 2026, while a permanent coding solution (new CPT) is not expected until 2028.Company Guidance
Revenue Growth Despite Headwinds
Revenue increased 1.6% year-over-year to $204.6 million in Q1 2026, driven by increased market penetration despite coding/reimbursement and WISER-related disruptions.
Improved Profitability Metrics and Margins
Adjusted EBITDA margin improved by 100 basis points to 17.5%; adjusted operating income and operating cash flow improved versus the prior year.
Operating Cash Flow and Strong Balance Sheet
Operating cash flow was $12.8 million for the quarter, an improvement of $20 million year-over-year. Cash and investments totaled $400 million with no debt.
Clinical and Scientific Momentum
Multiple clinical milestones: ADHERE 5,000-patient trial complete; PREDICTOR manuscript accepted for publication; full Inspire V Singapore trial results to be presented; independent VCU study published showing significantly lower odds of major cardiovascular events for Inspire patients. Company has treated >135,000 patients since inception.
Field Organization Optimization
Ended quarter with 284 U.S. territories and 288 U.S. field clinical reps, hired 13 field clinical reps in the quarter and reached goal of a one-to-one territory manager to field clinical rep ratio, plus targeted territory consolidation.
Product Flexibility and Inventory
Maintained inventory of Inspire IV to support centers concerned about Inspire V reimbursement; Q1 implant mix remained predominantly Inspire V but IV is available as a bridge.
INSP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INSP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $54.84 | $48.25 | -12.02% |
Feb 11, 2026 | $68.21 | $59.65 | -12.55% |
Nov 03, 2025 | $73.71 | $85.01 | +15.33% |
Aug 04, 2025 | $129.95 | $87.91 | -32.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inspire Medical Systems (INSP) report earnings?
Inspire Medical Systems (INSP) is schdueled to report earning on Aug 04, 2026, After Close (Confirmed).
What is Inspire Medical Systems (INSP) earnings time?
Inspire Medical Systems (INSP) earnings time is at Aug 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INSP EPS forecast?
INSP EPS forecast for the fiscal quarter 2026 (Q2) is -0.24.